BR112019010020A2 - compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20 - Google Patents

compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20

Info

Publication number
BR112019010020A2
BR112019010020A2 BR112019010020A BR112019010020A BR112019010020A2 BR 112019010020 A2 BR112019010020 A2 BR 112019010020A2 BR 112019010020 A BR112019010020 A BR 112019010020A BR 112019010020 A BR112019010020 A BR 112019010020A BR 112019010020 A2 BR112019010020 A2 BR 112019010020A2
Authority
BR
Brazil
Prior art keywords
compounds
cancer cells
activity against
cells containing
tumor activity
Prior art date
Application number
BR112019010020A
Other languages
English (en)
Inventor
Robichaux Jacqulyne
V Heymach John
Nilsson Monique
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of BR112019010020A2 publication Critical patent/BR112019010020A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

a presente invenção fornece métodos de tratamento de câncer em um paciente determinado para ter uma mutação do exon de egfr e/ou her2 20, tal como uma mutação de inserção, pela administração de um inibidor da tirosina quinase da terceira geração, tal como pozotinib ou afatinib.
BR112019010020A 2016-11-17 2017-11-17 compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20 BR112019010020A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662423732P 2016-11-17 2016-11-17
US201662427692P 2016-11-29 2016-11-29
US201762572716P 2017-10-16 2017-10-16
PCT/US2017/062326 WO2018094225A1 (en) 2016-11-17 2017-11-17 Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 mutations

Publications (1)

Publication Number Publication Date
BR112019010020A2 true BR112019010020A2 (pt) 2019-08-20

Family

ID=62146809

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019010020A BR112019010020A2 (pt) 2016-11-17 2017-11-17 compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20

Country Status (18)

Country Link
US (2) US11446302B2 (pt)
EP (1) EP3541832A4 (pt)
JP (2) JP7265985B2 (pt)
KR (2) KR20230145496A (pt)
CN (2) CN110291104B (pt)
AU (2) AU2017363199B2 (pt)
BR (1) BR112019010020A2 (pt)
CA (1) CA3044432A1 (pt)
CL (1) CL2019001353A1 (pt)
CO (1) CO2019006218A2 (pt)
CU (1) CU20190051A7 (pt)
EC (1) ECSP19043254A (pt)
MA (1) MA46852A (pt)
MX (1) MX2019005834A (pt)
PE (1) PE20191303A1 (pt)
PH (1) PH12019501116A1 (pt)
TW (1) TWI782931B (pt)
WO (1) WO2018094225A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202002060XA (en) * 2017-09-08 2020-04-29 Univ Colorado Regents Compounds, compositions and methods for treating or preventing her-driven drug-resistant cancers
WO2019191279A2 (en) * 2018-03-27 2019-10-03 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
AU2019292184A1 (en) * 2018-06-25 2020-12-17 Spectrum Pharmaceuticals, Inc. Combination of poziotinib with cytotoxic agent and/or other molecularly targeted agent and use thereof
CN112423745A (zh) * 2018-06-25 2021-02-26 光谱制药有限公司 波齐替尼与抗-her1抗体、抗-her2抗体或抗-her4抗体的组合物及其使用方法
TW202012391A (zh) * 2018-07-04 2020-04-01 日商第一三共股份有限公司 二芳基醚型喹唑啉衍生物
AU2019337640A1 (en) * 2018-09-14 2021-03-11 Spectrum Pharmaceuticals, Inc. Kits and methods for treating cancers
CN113056272A (zh) * 2018-09-21 2021-06-29 光谱医药公司 新的喹唑啉egfr抑制剂
CA3121807A1 (en) * 2018-12-21 2020-06-25 Board Of Regents, The University Of Texas System Combination therapy for the treatment of cancer
CN113840842A (zh) 2019-02-26 2021-12-24 詹森生物科技公司 利用双特异性抗EGFR/c-Met抗体的联合疗法和患者分层
JP2022527499A (ja) * 2019-03-29 2022-06-02 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｈｅｒ２エクソン２１挿入を有するがん細胞に対する抗腫瘍活性を有する化合物
US20220143023A1 (en) * 2019-03-29 2022-05-12 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions
CN113993592A (zh) * 2019-04-17 2022-01-28 得克萨斯大学体系董事会 针对携带酪氨酸激酶抑制剂耐药性egfr突变的癌症的化合物
US20220193074A1 (en) * 2019-04-17 2022-06-23 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing tyrosine kinase inhibitor resistant egfr mutations
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
JOP20210304A1 (ar) 2019-05-14 2023-01-30 Janssen Biotech Inc علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
AU2020337877A1 (en) * 2019-08-23 2022-03-17 Spectrum Pharmaceuticals, Inc. Poziotinib combination with VEGFR2 inhibitors and methods of use thereof
US20230069749A1 (en) * 2020-01-29 2023-03-02 Board Of Regents, The University Of Texas System Use of poziotinib for the treatment of cancers with nrg1 fusions
CN111658650B (zh) * 2020-05-28 2022-05-06 南通大学 Mln4924在制备脉络膜新生血管治疗药物中的应用
UY39342A (es) * 2020-07-27 2022-02-25 Spectrum Pharmaceuticals Inc Tratamiento con poziotinib para el cáncer de pulmón de células no pequeñas
EP4217070A1 (en) 2020-09-23 2023-08-02 Scorpion Therapeutics, Inc. Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer
WO2022072632A1 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Bicyclic compounds for use in the treatment cancer
WO2022072645A2 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022072634A1 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Bicyclic compounds for use in the treatment cancer
WO2022094271A1 (en) 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
US20240108623A1 (en) * 2021-01-29 2024-04-04 Board Of Regents, The University Of Texas System Methods of treating cancer with poziotinib
CN116997358A (zh) 2021-03-09 2023-11-03 詹森生物科技公司 对缺失egfr激活突变的癌症的治疗
WO2022197913A1 (en) 2021-03-18 2022-09-22 Scorpion Therapeutics, Inc. Bicyclic derivatives which can be used to treat cancer
WO2023015149A1 (en) * 2021-08-02 2023-02-09 Spectrum Pharmaceuticals, Inc. Treatment of non-small cell lung cancer with poziotinib
TW202342057A (zh) 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法
WO2023173083A1 (en) 2022-03-11 2023-09-14 Scorpion Therapeutics, Inc. Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer
CN117587111A (zh) * 2023-11-30 2024-02-23 苏州拓维生物技术有限公司 一种快速批量筛选化合物在激酶细胞系中活性的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042058A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
PT1667991E (pt) 2003-09-16 2008-07-14 Astrazeneca Ab Derivados de quinazolina como inibidores da tirosina cinase
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
EA200701619A1 (ru) 2005-02-04 2008-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Применение ингибиторов тирозинкиназы для лечения хронического риносинусита
PT2068880E (pt) * 2006-09-18 2012-07-12 Boehringer Ingelheim Int Método para tratamento do cancro apresentando mutações no egfr
CN101516376A (zh) * 2006-09-18 2009-08-26 贝林格尔.英格海姆国际有限公司 用于治疗携带egfr突变的癌症的方法
US8137919B2 (en) * 2008-04-10 2012-03-20 Montefiore Medical Center Method of determining the sensitivity of cancer cells to EGFR inhibitors including cetuximab, panitumumab and erlotinib
PE20100252A1 (es) 2008-06-06 2010-04-12 Boehringer Ingelheim Int Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
AU2013355260B2 (en) 2012-12-04 2019-07-25 Caris Mpi, Inc. Molecular profiling for cancer
PT3037424T (pt) * 2013-08-22 2017-12-18 Taiho Pharmaceutical Co Ltd Novo composto substituído com quinolina

Also Published As

Publication number Publication date
ECSP19043254A (es) 2019-09-30
US11446302B2 (en) 2022-09-20
JP7265985B2 (ja) 2023-04-27
WO2018094225A1 (en) 2018-05-24
JP2020502059A (ja) 2020-01-23
CN110291104A (zh) 2019-09-27
US20230233563A1 (en) 2023-07-27
CL2019001353A1 (es) 2019-11-08
EP3541832A4 (en) 2020-09-30
MA46852A (fr) 2019-09-25
TW201825098A (zh) 2018-07-16
CO2019006218A2 (es) 2020-01-17
US20200316071A1 (en) 2020-10-08
TWI782931B (zh) 2022-11-11
MX2019005834A (es) 2019-10-14
PH12019501116A1 (en) 2019-11-25
KR102585006B1 (ko) 2023-10-05
CN117599061A (zh) 2024-02-27
CN110291104B (zh) 2023-11-03
KR20190085980A (ko) 2019-07-19
JP2023100682A (ja) 2023-07-19
EP3541832A1 (en) 2019-09-25
AU2023266384A1 (en) 2023-12-07
AU2017363199B2 (en) 2023-08-17
KR20230145496A (ko) 2023-10-17
PE20191303A1 (es) 2019-09-23
AU2017363199A1 (en) 2019-07-04
CU20190051A7 (es) 2020-01-03
CA3044432A1 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
BR112019010020A2 (pt) compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
BR112021019489A2 (pt) Compostos com atividade antitumoral contra células cancerosas portando inserções do éxon 20 de egfr ou de her2
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
PH12015502161A1 (en) Therapeutic compounds and compositions
BR112016000810A2 (pt) imunoterapia contra vários tumores tais como câncer de pulmão, incluindo cpcnp
UA107667C2 (uk) Лікарські сполуки, що модулюють активність піруваткінази-м2, композиції на їх основі та застосування при лікуванні раку
MX2016007351A (es) Terapia de combinacion para tratar cancer.
MX2017013142A (es) Terapia combinada para tratar cáncer.
MX342274B (es) Actividades de la piruvato quinasa m2 (pkm2).
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX362215B (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
MX369664B (es) Composiciones de nanoparticulas inorganicas en combinacion con radiaciones ionizantes para tratar el cancer.
MX2020001727A (es) Terapia de combinacion.
MX2019010149A (es) Inhibicion del smarca2 para el tratamiento del cancer.
PH12020551495A1 (en) Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
EP4353320A3 (en) Blood plasma and plasma fractions as therapy for tumor growth and progression
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX2019013862A (es) Terapia de combinacion.
BR112022001690A2 (pt) Tratamento de tumores imunes evasivos
BR112021019376A2 (pt) Compostos com atividade antitumor contra células cancerígenas transportando inserções de éxon 21 de her2
TR201811308T4 (tr) Kanser kok hücrelerini azaltan anti-emp2 tedavisi.
CY1123818T1 (el) Syd985 θεραπεια δυσιατων me t-dm1 ασθενων με καρκινο
EA201690376A1 (ru) Ингибиторы дезоксицитидинкиназы

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements